Miguel Tovar

1,714 Added | 1 Magazine | 1 Following | 67 Followers | @MiguelTovar3nhq | about.me/tovar

Novartis CEO feels heat on U.S. generics, Cosentyx drop

ZURICH (Reuters) - Swiss drugmaker Novartis' first quarterly results under new CEO Vas Narasimhan have been marred by a prized psoriasis treatment that disappointed and a sharp slump in sales by its U.S. generics unit.<p>The stock declined 2.2 percent at 1200 GMT, more than double the fall of the …

Biotechnology

Experts query case for GlaxoSmithKline's new 3-in-1 lung drug

LONDON (Reuters) - Two medical experts have urged caution in using a new three-in-one inhaler for chronic lung disease from GlaxoSmithKline, which the company hopes will help it keep its lead in respiratory medicine despite rising competition.<p>Trelegy Ellipta was licensed for use last year and full …

Biotechnology

China's pharmaceutical industry is poised for major growth

China, the world's manufacturing powerhouse, is moving toward a more value-add economy and there's one major industry where the country could …

Biotechnology

P&G to buy German Merck's consumer health unit for $4.2 billion

(Reuters) - Procter & Gamble Co (P&G) has agreed to acquire Merck KGaA's consumer health unit for 3.4 billion euros ($4.2 billion), giving it vitamin brands such as Seven Seas and greater exposure to Latin American and Asian markets.<p>The maker of Pampers diapers and Gillette razors said the deal …

Procter & Gamble

GSK flags pharma M&A ambitions by poaching Roche deal-maker

LONDON (Reuters) - GlaxoSmithKline (GSK.L) signaled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche's (ROG.S) Genentech unit to lead a worldwide search for promising experimental products.<p>He is the first senior hire by GSK's new research and …

Biotechnology

Industry fears disruption as EU excludes UK from drug approvals

LONDON (Reuters) - A European decision to exclude Britain from the EU's drug approval system from March 30 2019 - the day after Brexit - has raised alarm among drugmakers, who fear the abrupt change could disrupt medicine supplies to patients.<p>The move confounds hopes for continued joint cooperation …

United Kingdom

Sanofi sells European generics to Advent for $2.4bn

The deal will create a new, independent European generics company

Biotechnology

Bristol Partners With Illumina On Diagnostic Test To Use With Opdivo

Drug giant Bristol-Myers Squibb is partnering with Illumina, the leading maker of DNA sequencing gear, to develop diagnostic tests that will pair with Bristol’s cancer drugs.<p>One of the first tests will be for tumor mutation burden, a measure of how much a tumor’s DNA has changed compared to the …

Biotechnology

Novartis CEO: How To Create Cheaper Alternatives To The Most Expensive Drugs

Recently, FDA Commissioner Scott Gottlieb addressed those in attendance at America’s Health Insurance Plans’ (AHIP) National Health Policy Conference. His comments created a lot of visibility around several critical topics, including patient access to innovative treatments, cost-effectiveness, and …

Pharma

Pfizer's Deal Potential Doesn't Stop at Bristol-Myers

Biopharma investors have enjoyed a recent streak of small-to-medium sized M&A, but they really hunger for something bigger. Pfizer Inc. is considered …

Biotechnology

Novartis bets big on gene therapy with $8.7 billion AveXis deal

ZURICH (Reuters) - Swiss drugmaker Novartis (NOVN.S) is moving further into gene therapy by buying AveXis (AVXS.O) for $8.7 billion, adding a rare-disease treatment that could reap billions in sales.<p>The acquisition reflects a surge of interest in biotech deal-making as large pharmaceutical …

Biotechnology

Pfizer in talks with P&G on sale of its consumer business, though they are far apart on price: Sources

Pfizer is in talks with Procter & Gamble on a sale of its consumer business, sources tell CNBC.<p>The business includes Chapstick lip balm, Advil pain …

Procter & Gamble

AI. Telemedicine. Quantum. New Novartis Boss Says Tech Will Finally Change The Drug Biz

What does the youngest chief executive in Big Pharma want? A control room straight off the starship Enterprise.<p>When Vas Narasimhan, 41, took the helm of drug giant Novartis in February, he’d already put the project in motion. Novartis scouts were dispatched to visit air traffic control towers and …

Biotechnology

GSK pulls out of $20 billion race for Pfizer consumer assets

LONDON (Reuters) - GlaxoSmithKline (GSK.L) has quit the race to buy Pfizer's (PFE.N) consumer healthcare business, endangering an auction the U.S. drugmaker hoped would bring in as much as $20 billion.<p>It was not immediately clear whether there were other offers for the business, which includes …

Biotechnology

A $158 Billion Drug Giant Faces an Identity Crisis

Blockbuster arthritis treatment Humira helped build AbbVie Inc. into a pharmaceutical-industry behemoth. Now investors are growing concerned about …

Biotechnology

Novartis touts U.S. filing plans for MS drug as patent losses loom | Reuters

ZURICH (Reuters) - Novartis plans to file its BAF312 multiple sclerosis drug for U.S. approval within weeks, the Swiss drugmaker said on Friday, as it seeks to refresh its portfolio of neurological medicines that is about to be hit by patent losses.<p>The logo of Swiss drugmaker Novartis is seen …

Novartis

GlaxoSmithKline in pole position for $20bn Pfizer unit

GlaxoSmithKline is in pole position to win the race for the consumer healthcare business of US pharma giant Pfizer, after it beat a rival bid from …

Pfizer

Novo Nordisk’s semaglutide obesity trial hits the mark

The injection helped adults lose up to 13.8% of their body weight in a year

Biotechnology

Patients regain sight with stem cell treatment in U.K. clinical trial

Nearly three years ago, 86-year-old Douglas Waters developed severe vision problems. He was diagnosed with severe wet age-related macular …

University College London
Diabetes

Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug

Foliglurax is currently in phase II testing for LID, muscle stiffness and ‘freezing’

Biotechnology

China pharma boosts generics exports to US

Chinese pharmaceutical companies are stepping up their push into the US generic drugs market with the number of approvals for copycat medicines …

Generic Drugs

Theranos and the Problem With Booming Biotech Funding

Theranos has been a big embarrassment for the world of private health-care investment. It deepened on Wednesday, when the SEC detailed what it called …

Biotechnology

Roche CEO says new drugs will offset biosimilar incursions

ZURICH (Reuters) - Swiss drugmaker Roche will be able to compensate or overcompensate for falling revenue from patent-expired drugs facing competition from rivals' copies through its new medicines, Chief Executive Severin Schwan said on Tuesday.<p>Schwan's outlook, delivered to shareholders at the …

Biotechnology

AstraZeneca Delays Final Results of Failed Lung-Cancer Trial

AstraZeneca Plc delayed the final results from its Mystic lung-cancer trial, which failed last year, to collect more data on how long patients live …

Cancer

In The War Against High Drug Prices, Some Patients Are Collateral Damage

Tommy Mann’s dad had his first heart attack when he was 29. That’s how he found out that he had a genetic disorder, familial hypercholesterolemia (FH), that causes very high cholesterol levels. Tommy and his two sisters have FH, too. Even on the top dose of cholesterol pills, Tommy Mann’s …

Pharma

Biogen to buy Pfizer's neurology drug in deal nearing $600 mln

March 12 (Reuters) - Biogen Inc said on Monday it would buy Pfizer Inc’s experimental treatment for cognitive impairment associated with schizophrenia in a deal whose value could near $600 million.<p>Biogen said it would pay Pfizer $75 million upfront, up to $515 million in development and …

Biotechnology

Novartis CEO: We Need a Different Approach to Drug Discovery

Heart disease remains the number one cause of death worldwide, accounting for more than 30% of all global deaths. Yet the discovery of new …

Digital Health

FDA's Gottlieb blames industry 'Kabuki drug pricing' for high costs

WASHINGTON (Reuters) - U.S. Food and Drug Administration chief, Scott Gottlieb, criticized pharmacy benefit managers, health insurers and drugmakers on Wednesday for "Kabuki drug-pricing constructs" that profit the industry at the expense of consumers.<p>The comments, made at a conference organized by …

FDA

Novartis pushes ‘virtual’ clinical trial concept

<b>Running clinical trials is an expensive business and Novartis has signed a new deal with US tech company Science 37 to try to take some of the costs</b> …